# Rocket One Inc.: financial statements, quarterly

RKTO · Nasdaq · CIK 1711786 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/rkto.md) · [Financials](/companies/rkto/financials.md) · [Filings](/companies/rkto/filings.md) · [Insiders](/companies/rkto/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rkto/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [1,235](/filings/0001213900-24-042906.md) | [0.0 d](/filings/0001213900-24-067131.md) | [0.0 d](/filings/0001213900-24-096778.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [1.3](/filings/0001013762-25-004108.md) | [0.8 d](/filings/0001013762-25-004108.md) | [0.6](/filings/0001213900-25-042043.md) | [0.6](/filings/0001213900-25-074968.md) | [1.0](/filings/0001213900-25-109220.md) | [1.0 d](/filings/0001213900-26-035625.md) | [2.0](/filings/0001213900-26-057726.md) | [1.0](/filings/0001213900-26-090048.md) | [1.6](/filings/0001213900-25-109220.md) | [1.3 d](/filings/0001213900-26-035625.md) | [1.5](/filings/0001213900-26-057726.md) | [2.0](/filings/0001213900-26-090048.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(2.2)](/filings/0001013762-25-004108.md) | [(1.8) d](/filings/0001013762-25-004108.md) | [(2.2)](/filings/0001213900-25-042043.md) | [(1.7)](/filings/0001213900-25-074968.md) | [(2.2)](/filings/0001213900-25-109220.md) | [(2.1) d](/filings/0001213900-26-035625.md) | [(3.5)](/filings/0001213900-26-057726.md) | [(2.2)](/filings/0001213900-26-090048.md) | [(4.1)](/filings/0001213900-25-109220.md) | [(2.6) d](/filings/0001213900-26-035625.md) | [(2.6)](/filings/0001213900-26-057726.md) | [(3.8)](/filings/0001213900-26-090048.md) |
| Net income | $m | [(2.2)](/filings/0001013762-25-004108.md) | [(1.8) d](/filings/0001013762-25-004108.md) | [(2.1)](/filings/0001213900-25-109220.md) | [(1.7)](/filings/0001213900-25-109220.md) | [(2.2)](/filings/0001213900-25-109220.md) | [(2.1) d](/filings/0001213900-26-035625.md) | [(3.5)](/filings/0001213900-26-090048.md) | [(2.2)](/filings/0001213900-26-090048.md) | [(4.1)](/filings/0001213900-25-109220.md) | [(2.7) d](/filings/0001213900-26-035625.md) | [(2.7)](/filings/0001213900-26-090048.md) | [(3.8)](/filings/0001213900-26-090048.md) |
| Diluted EPS | $ per share | [(0.63)](/filings/0001013762-25-004108.md) | not reported | [(0.49)](/filings/0001213900-25-042043.md) | [(0.25)](/filings/0001213900-25-074968.md) | [(0.32)](/filings/0001213900-25-109220.md) | not reported | [(0.27)](/filings/0001213900-26-057726.md) | [(0.17)](/filings/0001213900-26-090048.md) | [(0.30)](/filings/0001213900-25-109220.md) | not reported | [(0.17)](/filings/0001213900-26-057726.md) | [(0.19)](/filings/0001213900-26-090048.md) |
| Basic EPS | $ per share | [(0.63)](/filings/0001013762-25-004108.md) | not reported | [(0.49)](/filings/0001213900-25-042043.md) | [(0.25)](/filings/0001213900-25-074968.md) | [(0.32)](/filings/0001213900-25-109220.md) | not reported | [(0.27)](/filings/0001213900-26-057726.md) | [(0.17)](/filings/0001213900-26-090048.md) | [(0.30)](/filings/0001213900-25-109220.md) | not reported | [(0.17)](/filings/0001213900-26-057726.md) | [(0.19)](/filings/0001213900-26-090048.md) |

- Revenue: us-gaap:Revenues, us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [11.8](/filings/0001213900-23-086133.md) | [9.3](/filings/0001013762-25-004108.md) | [7.6](/filings/0001213900-24-042906.md) | [9.7](/filings/0001213900-24-067131.md) | [8.0](/filings/0001213900-24-096778.md) | [7.0](/filings/0001213900-26-035625.md) | [11.3](/filings/0001213900-25-042043.md) | [9.0](/filings/0001213900-25-074968.md) | [7.8](/filings/0001213900-25-109220.md) | [6.2](/filings/0001213900-26-090048.md) | [4.0](/filings/0001213900-26-057726.md) | [7.9](/filings/0001213900-26-090048.md) |
| Current assets | $m | [12.9](/filings/0001013762-25-004108.md) | [10.2](/filings/0001013762-25-004108.md) | [9.0](/filings/0001013762-25-004108.md) | [10.5](/filings/0001013762-25-004108.md) | [8.7](/filings/0001013762-25-004108.md) | [7.6](/filings/0001213900-26-035625.md) | [12.3](/filings/0001213900-25-042043.md) | [10.1](/filings/0001213900-25-074968.md) | [8.9](/filings/0001213900-25-109220.md) | [6.9](/filings/0001213900-26-090048.md) | [4.9](/filings/0001213900-26-057726.md) | [8.6](/filings/0001213900-26-090048.md) |
| Total assets | $m | [12.9](/filings/0001013762-25-004108.md) | [10.2](/filings/0001013762-25-004108.md) | [9.1](/filings/0001013762-25-004108.md) | [10.6](/filings/0001013762-25-004108.md) | [8.7](/filings/0001013762-25-004108.md) | [7.7](/filings/0001213900-26-035625.md) | [12.4](/filings/0001213900-25-042043.md) | [10.1](/filings/0001213900-25-074968.md) | [9.2](/filings/0001213900-25-109220.md) | [7.6](/filings/0001213900-26-090048.md) | [5.6](/filings/0001213900-26-057726.md) | [9.6](/filings/0001213900-26-090048.md) |
| Current liabilities | $m | [1.6](/filings/0001213900-23-086133.md) | [0.7](/filings/0001013762-25-004108.md) | [0.6](/filings/0001213900-24-042906.md) | [0.7](/filings/0001213900-24-067131.md) | [0.8](/filings/0001213900-24-096778.md) | [0.8](/filings/0001213900-26-035625.md) | [0.8](/filings/0001213900-25-042043.md) | [0.4](/filings/0001213900-25-074968.md) | [1.0](/filings/0001213900-25-109220.md) | [1.5](/filings/0001213900-26-090048.md) | [1.4](/filings/0001213900-26-057726.md) | [1.4](/filings/0001213900-26-090048.md) |
| Total liabilities | $m | [1.6](/filings/0001213900-23-086133.md) | [0.7](/filings/0001013762-25-004108.md) | [0.7](/filings/0001213900-24-042906.md) | [0.7](/filings/0001213900-24-067131.md) | [0.8](/filings/0001213900-24-096778.md) | [0.8](/filings/0001213900-26-035625.md) | [0.8](/filings/0001213900-25-042043.md) | [0.4](/filings/0001213900-25-074968.md) | [1.0](/filings/0001213900-25-109220.md) | [1.5](/filings/0001213900-26-090048.md) | [1.4](/filings/0001213900-26-057726.md) | [1.4](/filings/0001213900-26-090048.md) |
| Shareholders' equity | $m | [11.3](/filings/0001013762-25-004108.md) | [9.5](/filings/0001213900-26-035625.md) | [8.4](/filings/0001213900-25-109220.md) | [9.9](/filings/0001213900-25-109220.md) | [7.9](/filings/0001213900-25-109220.md) | [6.9](/filings/0001213900-26-090048.md) | [11.5](/filings/0001213900-26-090048.md) | [9.7](/filings/0001213900-26-090048.md) | [8.2](/filings/0001213900-25-109220.md) | [6.2](/filings/0001213900-26-090048.md) | [4.2](/filings/0001213900-26-090048.md) | [8.2](/filings/0001213900-26-090048.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,637) d](/filings/0001013762-25-004108.md) | [(3,071) d](/filings/0001013762-25-004108.md) | [(1,724)](/filings/0001213900-25-042043.md) | [(1,592) d](/filings/0001213900-25-074968.md) | [(1,635) d](/filings/0001213900-25-109220.md) | [(2,028) d](/filings/0001213900-26-035625.md) | [(2,788)](/filings/0001213900-26-057726.md) | [(2,373) d](/filings/0001213900-26-090048.md) | [(2,493) d](/filings/0001213900-25-109220.md) | [(2,150) d](/filings/0001213900-26-035625.md) | [(3,051)](/filings/0001213900-26-057726.md) | [(2,969) d](/filings/0001213900-26-090048.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.3](/filings/0001213900-23-086133.md) | [2.5](/filings/0001213900-24-042906.md) | [3.3](/filings/0001213900-24-067131.md) | [3.5](/filings/0001213900-24-096778.md) | [4.4](/filings/0001213900-25-042043.md) | [6.9](/filings/0001213900-25-074968.md) | [6.9](/filings/0001213900-25-109220.md) | [12.7](/filings/0001213900-26-057726.md) | [13.2](/filings/0001213900-26-090048.md) | [13.8](/filings/0001213900-25-109220.md) | [15.8](/filings/0001213900-26-057726.md) | [20.5](/filings/0001213900-26-090048.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 24,897,581 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001213900-26-090048.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.